Kirk Look to speak todayThat's just what we want, a non-scientist talking at a fireside chat about Pela's development. Perhaps he will share how he intends to pay for this next Phase II trial...
and bear in mind folks, the data may not facilitate AA.. and thus we will be into Phase III territory...
Interesting that the PanCAn trial was going to save ONCY about 40 million... Matt's words... half the cost it would normally be...
So, since mBC won't have the comparator arm study already done... we're looking at 80 million again... that's more than ONCY is worth... if anyone is attending, do ask Kirky how he will fund two phase III's without a partner?
oooh wait, there is a partner... Adlai Nortye... who no longer list Pela in their pipeline... and they completed theoir bridging trial in Jun 2023... I wonder why they aren't running a Phase III for China or even mentioning it anymore.
Hands up if you think the PPS will rise after the call... or will it drop as it normally does... meanwhile Palantir is in the S&P 500... hoozah for great companies with clever management.